HMG-CoA reductase inhibitor improves endothelial dysfunction in spontaneous hypertensive rats via down-regulation of caveolin-1 and activation of endothelial nitric oxide synthase. by �옣�쁺�옱
INTRODUCTION
Endothelial dysfunction is a major early pathologic change
and is detected long before the appearance of overt atheroscle-
rotic disease in hypertension. Recent experimental and clin-
ical studies showed acetylcholine, not sodium nitroprusside
(SNP), induced vasodilatation is impaired in resistance or
conduit arteries from hypertensive patients and animal mod-
els. Nitric oxide/endothelial nitric oxide synthase (NO/eNOS)
system plays a major role in endothelium dependent vasodi-
latation along with other vasoactive substances in blood vas-
culature (1, 2). The impairment of endothelium-dependent
dilatation, which is accompanied by the alteration in the ex-
pression and/or activity of the endothelial NO synthase, has
consistently been observed in conduit arteries and resistance
vessels as an effect of hypertension (3, 4). 
NO, which is responsible for acetylcholin-induced vasodi-
lation, has been reported to be reduced both in circulation
(5), and endothelium (6) in hypertensive subjects. Nitric oxide
is synthesized by eNOS, one of a family of heme-containing
enzymes that catalyzes the guanidinium moiety of L-arginine
to NO and L-citrulline (7). In endothelial cells, eNOS expres-
sion and activity are precisely controlled in transcriptional or
post-translational levels by protein-protein interactions, Ca2+
concentration and its subcellular distribution (8, 9). Reduced
NO generation, without change of eNOS expression, may
result from depressed activity of eNOS as a result of endoge-
nous or exogenous inhibitors, reduced substrate L-arginine,
decreased cofactor tetrahydrobiopterin (BH4) or decreased
bioavailability of NO by increased reactive oxygen species
(10, 11).
Caveolae are membrane microdomains, which function as
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HMG-CoA Reductase Inhibitor Improves Endothelial Dysfunction in
Spontaneous Hypertensive Rats Via Down-regulation of Caveolin-1
and Activation of Endothelial Nitric Oxide Synthase
Hypertension is associated with endothelial dysfunction and increased cardiovas-
cular risk. Caveolin-1 regulates nitric oxide (NO) signaling by modulating endothe-
lial nitric oxide synthase (eNOS). The purpose of this study was to examine whether
HMG-CoA reductase inhibitor improves impaired endothelial function of the aorta in
spontaneous hypertensive rat (SHR) and to determine the underlying mechanisms
involved. Eight-week-old male SHR were assigned to either a control group (CON,
n=11) or a rosuvastatin group (ROS, n=12), rosuvastatin (10 mg/kg/day) adminis-
tered for eight weeks. Abdominal aortic rings were prepared and responses to acetyl-
choline (10-9-10-4 M) were determined in vitro. To evaluate the potential role of NO
and caveolin-1, we examined the plasma activity of NOx, eNOS, phosphorylated-
eNOS and expression of caveolin-1. The relaxation in response to acetylcholine
was significantly enhanced in ROS compared to CON. Expression of eNOS RNA
was unchanged, whereas NOx level and phosphorylated-eNOS at serine-1177 was
increased accompanied with depressed level of caveolin-1 in ROS. We conclude
that 3-Hydroxy-3-methylglutaryl Coenzyme-A (HMG-CoA) reductase inhibitor can
improve impaired endothelial dysfunction in SHR, and its underlying mechanisms
are associated with increased NO production. Furthermore, HMG-CoA reductase
inhibitor can activate the eNOS by phosphorylation related to decreased caveolin-
1 abundance. These results imply the therapeutic strategies for the high blood pres-
sure-associated endothelial dysfunction through modifying caveolin status.
Key Words : Hydroxymethylglutaryl-CoA Reductase Inhibitors; Caveolins; Nitric Oxide; Nitric Oxide Syn-
thase Type III
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mobile signaling platforms in the plasma membrane, and pre-
sent ubiquitously in endothelial cells (12). Caveolin-1 is the
22-kDa protein constituent of caveolae, which finely tunes
various physiological roles such as activating enzymes as eNOS,
modulating signal proteins and mediating transcytosis (13).
Caveolin regulates eNOS activity by holding it at scaffold
domain in inactive states in vitro. After eNOS is dissociated
from caveolin-1 by external stimulation, it forms the com-
plex with calcium/calmodulin or heat shock protein 90. And,
then, the eNOS would be activated and increase the NO pro-
duction (14). Furthermore, the importance of caveolin is in-
creasingly recognized as functioning signalosome and medi-
ator in various diseases such as atherosclerosis, pulmonary
hypertension and diabetes (15). In hypertension, caveolin ex-
pression is also identified to be increased in endothelial cell
and vascular smooth muscle cell and implicated as anti-hyper-
tensive target (16).
3-Hydroxy-3-methylglutaryl Coenzyme-A (HMG-CoA)
reductase inhibitors, statins, are the most widely used choles-
terol lowering agent, which provide the additional beneficial
effects independent of cholesterol lowering. Beneficial effects
independent of lipid lowering can also contribute to prevent
the atherosclerosis in various populations of patients. The
cholesterol-independent or ‘‘pleiotropic’’ effects of statins in-
volve improvement of endothelial function, stability of athe-
rosclerotic plaques, decrease of oxidative stress and inflam-
mation, and inhibition of thrombogenic response (17). Pre-
vious studies have demonstrated that statins can stimulate
NO release from endothelial cells by eNOS activation. And,
the phosphorylation of eNOS may explain, in part, a mecha-
nism of statin-induced eNOS activation and NO release (18).
The aim of this study was to examine whether the HMG-
CoA inhibitor, rosuvastatin, alleviates impaired endothelium
dependent vasodilatation of the aorta in spontaneous hyper-
tensive rat (SHR) and to investigate the underlying mecha-
nisms involved. 
MATERIALS AND METHODS
Animals
Eight week-old SHRs were purchased from SLC, Inc., Japan.
The animals were fed with a standard rat chow (CE-2 contain-
ing 0.5% NaCl, Purina, Inc., Seoul, Korea) and free access
to tap water. SHR were assigned to either a control group
(CON, n=11) or a rosuvastatin group (ROS, n=12), rosuvas-
tatin (10 mg/kg/day) was mixed with chow and administer-
ed for eight weeks. The amount of rosuvastatin blended with
chow was estimated from the weight of chow taken in the
previous days. Body weight, serum fasting glucose, choles-
terol level, insulin activity were measured. This study was
approved by the Animal Care Committee of Seoul National
University Bundang Hospital, and followed its recommen-
dation.
Evaluation of vasodilator responses
Vascular relaxations were measured as previously reported
(11). In brief, thoracic rings (3-4 mm in length) were suspend-
ed in the Krebs solution and oxygenated with 95% O2 and
5% CO2, at 37℃. The rings were contracted maximally with
10-5 M phenylephrine and the endothelin-dependent and -in-
dependent relaxations were studied in responses to 109-105
M/L acetylcholine (Ach; Sigma, St. Louis, MO, USA), and to
109-105 M/L sodium nitroprusside (SNP; Sigma), respectively.
Endothelium-dependent and -independent relaxation was
expressed as the percentage decline of contraction induced by
phenylephrine. 
Plasma nitrite and nitrate assay
Plasma nitrite and nitrate levels were measured with the
Griess method (5). Briefly, the blood samples collected from
left ventricular cavity of the rats were added to a microcen-
trifuge tube containing heparin sodium. The heparin-treat-
ed blood samples were centrifuged at 5,000 g, for 10 min,
at 4℃ and the plasma was collected. Eighty mL of plasma
was mixed with 10 mL of 5 mM b-NADPH, 10 mL (10 U)
of nitrate reductase. The samples were allowed to incubate
for 1 hr at 37℃ in the dark. Then, 100 mL of Griess reagent
(0.1% N-[1-naphthyl] ethylenediamide dihydrochloride, 1%
sulfanilamide in 5% phosphoric acid), followed by spectro-
photometric measurement at 550 nm. Plasma nitrite and
nitrate concentrations in the supernatants were determined
by comparison with a sodium nitrite standard curve. 
Real time RT-PCR for eNOS expression in aortic tissue
The endothelium and media of aorta was manually sepa-
rated from adventitia under dissection microscope and homog-
enized in lysate buffer. And the total RNA was isolated using
the RNAqueous filter system (Ambion, Austin, TX, USA).
Two mg of total RNA was used to perform real-time PCR.
cDNA was synthesized with reverse transcriptase and two
mL of cDNA was used for real time PCR. The commercial
primer of the sequence for rat eNOS (forward primer: GAA
CCT ACA GAG CAG CAA ATC CA; reverse primer: CAG
TCC CTC CTG GCT TCC TCC A) and the TaqMan probe
(probe: CGA GCC ACA ATC CTG GTC CGT CTT) were
used. The reactions were accomplished in triplicate for the
samples. The PCR was started at 95℃ for ten minutes fol-
lowed by 40 two-step cycles of 15 sec at 95℃ and then 1 min
at 60℃ by the ABI Prism 7700 Sequence Detection system.
Levels of the expression of eNOS as target sequence were quan-
tified by calculating the difference between the target and
co-amplified 18S ribosomal RNA. 
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Western blot analysis for caveolin-1, eNOS and phospho-
eNOS protein 
Immunoblotting of rat aorta was carried out as previously
described (12, 18). The stripped aorta was homogenized and
eNOS, phosphorylated eNO and caveolin-1 protein expres-
sion was measured in the supernatant of homogenates. SDS/
PAGE (12% [w/v] polyacrylamide) was performed. The pro-
tein was transferred on to PVDF and incubated with prima-
ry polyclonal anti-caveolin-1 antibody (1:1,000; BD, Frank-
lin Lakes, NJ, USA), monoclonal anti-eNOS antibody (1:
1,000; Cell Signaling Technology, Inc., Boston, MA, USA)
and anti-phospho-eNOS ser 1177 antibody (1:1,000; Cell
Signaling Technology, Inc.) overnight at 4℃. The membrane
was washed and then incubated with a horseradish peroxi-
dase-conjugated anti-rabbit secondary antibody at room tem-
perature for 1 hr. The immunoreactivity on the membrane
was detected using enhanced chemiluminescence (Amersham,
Little Chalfont, UK) following the manufacturer’s instruc-
tion. Normalization for loading differences was accomplished
using ratios of the densitometry signals for actin (1:2,000;
Calbiochem, Darmstadt, Germany) versus caveolin-1, eNOS
or phospho-eNOS protein.
Immunohistochemistry
Tissue preparation was carried out as previously described
(16). Briefly, the aortas were fixed with paraformaldehyde in
a 0.05 M phosphate buffer (pH 7.4) and cryoprotected with
30% sucrose solution serially and sectioned at 10 mm. The
sections were incubated with polyclonal anti-caveolon-1 anti-
body (1:200 diluted in PBS) for 3 hr at room temperature
followed by 1 hr in biotin-conjugated anti-rabbit antibody
(Jackson Immunoresearch Lab, West Grove, PA, USA). The
sections were then incubated with streptavidin HRP conju-
gate (Zymed Laboratories, San Francisco, CA, USA) at a 1:
150 dilution, and visualized using the aminoethyl carbazole
substrate. The sections were then counterstained with Mayer
hematoxylin (Sigma).
Statistical analysis
All statistical tests were performed using the SPSS for Win-
dows� (version 15.0, Chicago, IL, USA). Values are expressed
as mean±standard error of means. Differences in categori-
cal values between the two groups were analyzed using the
chi-square test and differences in continuous variables were
analyzed using the Student’s t-test. P values of <0.05 were
considered statistically significant.
RESULTS
Baseline data
The body weight was similar in each group at the baseline.
The change of body weight was higher in rosuvastatin group
after 8 weeks, but the difference was not statistically signifi-
cant (CON vs. ROS; 135.8±15.9 g vs. 148.5±9.9 g, P=
NS). The plasma level of total cholesterol (CON vs. ROS;
69.5±4.5 mg/dL vs. 65.7±6.3 mg/dL, P=NS), Triglyc-
eride (CON vs. ROS; 80.7±19.7 mg/dL vs. 70.0±13.7 mg/
dL, P=NS) and HDL-cholesterol (CON vs. ROS; 27.9±1.5
mg/dL vs. 27.0±2.2 mg/dL, P=NS) was not different after
eight weeks in each group (Table 1). Blood pressure profile
after eight week treatment, at fourteen week-age, did not
show the statistical difference between each group, even if
rosuvastatin-treated group showed the tendency to have lower
systolic (CON vs. ROS; 191.9±14.2 mg/dL vs. 186.7±
22.1 mg/dL, P=NS) and diastolic blood pressure (CON vs.
ROS; 147.0±9.0 mg/dL vs. 144.8±18.2 mg/dL, P=NS)
(Table 2). 
Endothelium dependent and independent relaxation
The dose-dependent relaxation response to acetylcholine
was achieved in both rosuvastatin-treated and control groups
Control
(n=11)
ROS
(n=12)
P
Body weight (6-weeks) 203.8±6.1 206.8±2.9 NS
Body weight (14-weeks) 341.0±13.9 349.1±15.5 NS
DBWt 135.8±15.9 148.5±9.9 NS
Glucose (mg/dL) 161.5±31.1 158.6±33.1 NS
Total cholesterol (mg/dL) 69.5±4.5 65.7±6.3 NS
Triglyceride (mg/dL) 80.7±19.7 70.0±13.7 NS
HDL-cholesterol (mg/dL) 27.9±1.5 27.0±2.2 NS
Table 1. Body weight and lipid profile in rosuvastatin-treated
SHR and control SHR. Body weights were measured at base-
line and after the experimental treatment period, and plasma
concentrations of total cholesterol, triglyceride and HDL-choles-
terol were determined after the experimental treatment period
Control (n=11)At 14-week ROS (n=12) P
SBP (mmHg) 191.9±14.2 186.7±22.1 NS
DBP (mmHg) 147.0±9.0 144.8±18.2 NS
MBP (mmHg) 162.0±9.9 154.6±26.7 NS
PP (mmHg) 44.8±10.6 41.8±6.25 NS
Table 2. Blood pressure profiles in rosuvastatin-treated SHR and
control SHR. Blood pressures were measured after the experi-
mental treatment period
Data are expressed as mean±SEM.
SHR, spontaneous hypertensive rat; SBP, systolic blood pressure; DBP,
diastolic blood pressure; MBP, mean blood pressure; PP, pulse pres-
sure; ROS, reactive oxygen species.
Data are expressed as mean±SEM.
SHR, spontaneous hypertensive rat; HDL, high density lipoprotein choles-
terol; ROS, reactive oxygen species. 
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with maximal dilatation at maximum concentration (Ach 10-5
M). The relaxation in response to acetylcholine at a dose range
of 10-9 to 10-6 M was significantly greater in rosuvastatin-treat-
ed group than control group. The peak difference between
two groups was seen at Ach 10-8 M. (ROS vs. CON; 82.3±
6.6% vs. 73.3±4.8%, P<0.05) However, the maximum relax-
ation (Ach) between two groups showed no significant differ-
ence (Fig. 1A). The response to SNP, a known stimulant for
endothelium independent vasodilatation, dose-dependent
relaxation response was achieved in both groups without sig-
nificant differences, which maximum response was at SNP
10-6 M (101.4±2.7% vs. 100.6±3.4%, P=0.32) as well as
relaxation to other doses of SNP were similar for the aortic
rings of ROS and CON groups (Fig. 1B). 
Nitrite and nitrate bioactivity in plasma
Nitrite and nitrate activity in plasma was measured to esti-
mate the nitric oxide bioactivity. The measured plasma nitrite
and nitrate was significantly increased in rosuvastatin-treat-
ed group compared with control group (CON vs. ROS; 7.6
±3.0 mM vs. 12.5±4.5 mM, P<0.05) (Fig. 2).
Expression of eNOS in the aorta
The real time RT-PCR, evaluating the mRNA expression
of eNOS in the aorta could not show the difference between
rosuvastatin-treated group and control group (Fig. 3A). The
protein expression level of eNOS in the aorta was also not dif-
ferent between two groups. However, the level of phosphory-
lated eNOS, using antibody for Ser1177 of eNOS, was much
higher (�2.3 times) in rosuvastatin-treated group than con-
trol group (Fig. 3B).
Down regulation of caveolin-1 by rosuvastatin 
The treatment with rosuvastatin (10 mg/kg/day) for 8 weeks
resulted in decrease in the protein expression of caveolin-1
in the aorta of SHRs. Immunoblot analysis of aorta extract
showed a much lower caveolin-1 expression in the rosuvas-
tatin treated rats than the control group (Fig. 4). Immunos-
taining of the aorta with anti-caveolin-1 antibody showed a
discrete caveolin-1 expression in the endothelial cells. Caveoiln-
1 expression was decreased by rosuvastatin treatment, which
was demonstrated by the lower expression level in rosuvas-
tatin treated rats compared to control rats (Fig. 5).
DISCUSSION 
In this study, we demonstrated that HMG-CoA reductase
Fig. 2. Plasma nitrite and nitrate concentration is increased in rosu-
vastatin-treated group. NOx concentration in plasma, represent-
ing the circulating pool of bioactive nitrate and nitrite, was approx-
imately 1.6 fold higher in rosuvastatin-treated group than control
group. 
Column=mean values, error bar=standard error. *P<0.05 as com-
pared to the control.
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Fig. 1. Treatment of rosuvastatin (10 mg/kg/day) for 8 weeks significantly enhances endothelium-dependent vasodilatation in the aorta of
SHRs. (A) Aortic rings from rosuvastatin-treated SHRs exhibit a significantly higher response to acetylcholine-induced vasorelaxation com-
pared with control SHRs (n=8 for each group). (B) Addition of NO analog, sodium nitroprusside, to the medium induced complete vasore-
laxation, indicating maintenance of proper smooth muscle cell function in SHRs. 
Column=mean values, error bar=standard error. *P<0.05 as compared to the control.
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inhibitor, rosuvastatin, improved the endothelial dysfunction
in hypertensive animal without hypercholesterolemia. The
hypertension-related endothelial dysfunction seems to occur,
at least partly, via a NO-dependent mechanism. Previous
studies demonstrated that HMG-CoA reductase inhibitors
improved the endothelial dysfunction in hypertensive sub-
jects and its improvement is related to the antioxidant and
anti-inflammatory effects irrespective of plasma cholesterol
level (19).
The important findings of this study are as follows. First,
HMG-CoA reductase inhibitor improved endothelium-de-
pendent vasodilatation of the aorta in the hypertensive ani-
mal model, SHR. Second, the improvement of endothelial
function by HMG-CoA reductase inhibitor was accompani-
ed by enhanced plasma nitrite and nitrate level reflecting the
enhanced production of nitric oxide in endothelium. Third,
HMG-CoA reductase inhibitor enhanced the phosphoryla-
tion of the eNOS to increase the level of activated eNOS, and
subsequently, enhanced the production of nitric oxide with-
out altering the expression level of eNOS. Finally, HMG-CoA
reductase inhibitor decreased the expression of caveolin-1 in
endothelium of aorta, which could modulate the degree of
phosphorylation and, ultimately, enhance the activity of the
eNOS. 
HMG-CoA reductase inhibitors are widely used in clinical
practice and prescribed for the treatment of hypercholestero-
lemia. Recent clinical and experimental studies have shown
that statins have pleiotropic effects, beside modulating lipid,
such as anti-inflammatory, anti-proliferative, anti-thrombot-
ic effects, and improving endothelial vasomotor function,
all of which may affect cardiovascular outcomes in high risk
patients including hypertension (20). In our study, rosuvas-
tatin improved the endothelial dependent vasodilatation in
hypertensive rat model without changes of plasma choles-
terol level. These results imply that the pleiotropic effect of
HMG-CoA reductase inhibitor may play an important role
in improving endothelial function unrelated to changes of
cholesterol level in hypertension.
Endothelial dysfunction, a precursor to atherosclerotic dis-
ease, is favorably affected by HMG-CoA reductase inhibitors.
However, the mechanism of the effect of HMG-CoA reduc-
tase inhibitors on endothelial function remains unclear. One
proposed mechanism for this observation is augmentation
of endothelial nitric oxide (NO) bioavailability, resulting in
enhanced endothelium-dependent vasodilation. An experi-
Fig. 3. (A) eNOS mRNA expression in aorta from rosuvastatin-treated or control SHRs. mRNA expression of eNOS was not different bet-
ween two groups. (B) Protein expression of eNOS was also not different between two groups. However, phosphorylated eNOS (p-eNOS)
was expressed much higher (�2.3 fold) in rosuvastatin-treated compared with control SHRs. The expression level of p-eNOS was deter-
mined by western blot with monoclonal-anti-phospho-eNOS antibody at Ser1177. 
Column=mean values, error bar=standard error. *P<0.05 as compared to the control.
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Fig. 4. Assessment of the effect of rosuvastatin on caveolin-1 pro-
tein in the aorta of rats Top: Immunoblot of caveolin-1 protein in
the aorta (lane 1, 2, 3, and 4, aorta from control SHR; lane 5, 6, 7,
and 8, aorta from the rosuvastatin-treated SHR). Bottom: quanti-
fied data for caveolin-1 protein in rosuvastatin-treated and control
SHRs. Optical density caveolin-1 positive bands were quantified
by scanning densitometry and plotted relative to the control. 
Column=mean values, error bar=standard error. *P<0.01 as com-
pared to the control.
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mental study demonstrated that HMG-CoA reductase inhi-
bitor improved endothelial dysfunction via reduction of reac-
tive oxygen product and increased expression of eNOS (21).
Another evidence for nitric oxide theory is supported from
human and animal experimental data showing an increase in
endothelial NO production with statin treatment (22). In
this study, eight-week treatment of rosuvastatin improved
the endothelial function compared with control group (Fig. 1)
and increased the nitric oxide metabolite, NOx, in plasma
(Fig. 2).
After synthesis and release from the endothelium, nitric oxide
rapidly undergoes reaction in the blood to produce molecules,
including nitrite, nitrate, nitrosothiol proteins and a-nitrosyl
hemoglobin. The plasma nitrite and nitrate concentrations
are stable and reliable measure of systemic nitric oxide pro-
duction and their major source is endothelium (5). In this
study, the increased plasma level of nitrite and nitrate indi-
rectly represented the enhanced generation of endogenous
nitric oxide in endothelium after treatment of rosuvastatin,
which is well correlated to acetylcholine induced endotheli-
um-dependent dilatation (Fig. 1). Furthermore, two groups
have been fed with same chow and water for exogenous nitric
oxide source under same environment.
The mechanisms of the effect of HMG-CoA reductase inhi-
bitors on nitric oxide bioavailability have not been verified
thoroughly. It was demonstrated that HMG-CoA reductase
inhibitors could increase nitric oxide production without alter-
ing the expression of eNOS in vitro (18). These findings sug-
gest HMG-CoA reductase inhibitors can enhance the nitric
oxide production by modulating eNOS activity or other gene
products besides regulating the expression of eNOS. The nitric
oxide production can also increase by alterations in other mole-
cular system such as caveolin, HSP90 or Cu/Zn superoxide
dismutase (14). Recent studies demonstrated selected HMG-
CoA reductase inhibitors increased nitric oxide production
through HSP90 related mechanism in endothelial angiogen-
esis model. Treatment with HMG-CoA reductase inhibitor
increases eNOS phosphorylation by depressing expression of
caveolin-1 or promoting interaction of eNOS with HSP90
or Ca2+/CaM, which makes eNOS activated (18, 23).
The role of eNOS phosphorylation has been elucidated as
a determining factor for its own activation, interplaying with
its subcellular localization. eNOS is localized to, at least, two
subcellular compartments, one of which is the Golgi in per-
inuclear lesions and the other is the caveolae in the plasma
membrane. Membrane bound eNOS is estimated to be more
constitutively active and usually phosphorylated by Akt for
activation. In addition to the localization in subcellular com-
partment, binding of eNOS with caveolin-1 inhibits the acti-
vation of eNOS and suppresses the nitric oxide production
(24). Isolated aortic rings from caveolin-1 null animals were
unable to establish a steady-state contractile tone. When acetyl-
choline was added to the media to stimulate vasorelaxation,
the aortic rings from caveolin-1 null mice showed a signifi-
cantly greater relaxation response than wild-type control rings
(25). In SHR, the depressed basal production of bioactive
NO was associated with increased expression of eNOS and
decreased expression of caveolin-1. At this condition, cave-
olin-1 played a role as a negative modulator of eNOS to main-
tain the production of bioactive NO as compensatory mech-
A B
Fig. 5. Down-regulation of caveolin-1 by treatment of rosuvastatin in aortic endothelium of SHRs. The expression of caveolin-1 in aortic
endothelium of control SHR (A), and rosuvastatin-treated SHR (B). The level of expression of caveolin-1 was determined by immunohisto-
chemical staining with polyclonal-anti-caveolin-1 antibody. Endothelial cells of the aorta were stained and the arrow indicates caveolin-1.
Control
×400
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anism (26).
Several eNOS phosphorylation site, including serine-1177,
has important roles in regulating nitric oxide synthesis under
various physiological and pathological conditions (14). HMG-
CoA reductase inhibitor augments the phosphorylation of
eNOS at serine-1177 to increase eNOS activity. Increased
phosphorylation at this site by statin is an important mech-
anism to increase NO production. Ultimately, sustained phos-
phorylation at serine-1177 is an important factor for the long-
term regulation of NO release after statin-stimulated (18).
This study demonstrates that HMG-CoA reductase inhibitor
increased the eNOS phosphorylation at serine-1177 and en-
hanced nitric oxide bioavailability without change of eNOS
expression accompanied with improved endothelial function.
We demonstrates the rosuvastatin improved endothelium
dependent vasodilatation and it was associated with increased
nitric oxide bioavailability associated reduced caveolin-1 ex-
pression and increased eNOS phosphorylation without changes
of eNOS expression in endothelium. These findings suggest
that the depressed level of caveolin-1, mediated by HMG-
CoA reductase inhibitor, can enhance the phosphorylation
and activity of eNOS with decreasing membrane bound form,
without change of expression, to increase nitric oxide produc-
tion. This study revealed the effect of HMG-CoA reductase
inhibitor on the endothelial dysfunction via caveolin-1 and
eNOS/NO in hypertension, as in other pathologic conditions
(27) or in healthy subjects (28).
Baseline characteristics and lipid profiles of two groups were
similar. After 8 week treatment of HMG-CoA reductase inhi-
bitor or placebo, the plasma level of total cholesterol was also
not different between two groups. Because plasma lipid lev-
els are normally low in rats (in contrast with human beings)
and because statins is usually the lack of hypocholesterolemic
effect and do not modify lipid profile in rats, they provide an
excellent model for studying the other cardiovascular effects
(pleiotropic effect) of statins. Our result is in agreement with
a recent report in diabetic rats receiving the even higher dosage
of rosuvastatin (20 mg/kg/day) without lowering the level
of cholesterol (29).
This study has several limitations. First, direct causal rela-
tion or proportion of contribution of caveolin-1 with eNOS
activation was not proven in this study. In order to prove this
linkage, we need caveolin inhibitor, which is not available
nowadays, unfortunately. However, recent studies already
proved that the caveolin-1 modulate the activation of eNOS
in harmony with other signal molecule as Akt, CaMK, PKA,
PKC and Hps90 (14). We also demonstrated the increased
phosphorylation of Akt in this animal with HMG-CoA reduc-
tase inhibitor (data not shown). The contribution of these sig-
nal molecules to activity of eNOS would be changed by ex-
ternal stimulation or environmental factors. In this study, even
though the exact portion of contribution was not clarified,
it is clear that caveolin-1, at least partly, modulates the activ-
ity of eNOS under effect of HMG-CoA reductase inhibitor. 
Second, rosuvastain treated group showed the trend of lower
systolic, diastolic and mean blood pressure without statisti-
cal significance in hemodynamic data (Table 2). Some clini-
cal and experimental studies showed that HMG-CoA reduc-
tase inhibitor therapy slightly reduced blood pressure. And,
furthermore, the changes in blood pressure may influence the
endothelial function. As HMG-CoA reductase inhibitor have
pleiotropic effects on the vasculature, reduction in blood pres-
sure was accompanied by normalization of endothelial dys-
function, restoration of vasoconstriction to endothelin-1, inhi-
bition of vascular oxidative stress, angiotensin II blocking
and upregulation of vascular endothelial NO synthase activ-
ity. However, to date, evidence supporting the lowering of
blood pressure by HMG-CoA reductase inhibitor is limited
to a diminutive number of studies with small sample sizes
(30). To elucidate the anti-hypertensive effect of HMG-CoA
reductase inhibitor, the more intensive studies with sufficient
number of subject should be attempted.
Attenuated endothelium dependent vasodilation of the aorta
in SHR is improved by eight week-treatment with HMG-
CoA reductase inhibitor. It is at least partly associated with
increased NO production accompanied by decreased caveolin-
1 expression and altered phosphorylation of eNOS. This result
may imply the new therapeutic strategies, regarding caveolin
status, to increase endothelial NO generation with HMG-
CoA reductase inhibitors in hypertensive subject.
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